Market News & Trends
Ventyx Biosciences Announces Completion of Enrollment of Phase 2 Trial of VTX002 in Ulcerative Colitis & Phase 2 Trial of VTX958 in Plaque Psoriasis
Ventyx Biosciences, Inc. recently announced it has completed patient enrollment in the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 SERENITY…
Axol Bioscience Collaborates With StrataStem to Deliver Stem Cell-Based ‘Clinical Trial in a Dish’ for Alzheimer’s Disease
Axol Bioscience Ltd. has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples…..
Ocular Therapeuti Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy
Ocular Therapeutix, Inc. recently announced completion of enrollment in the HELIOS clinical trial of OTX-TKI. Using Elutyx technology, OTX-TKI is the company’s axitinib intravitreal implant…
European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator for Use in Patients With Diabetic Nephropathy/Diabetic Kidney Disease
ZyVersa Therapeutics, Inc. recently announces the European Patent Office has issued a “Notice of Intention to Grant” ZyVersa’s patent application covering the company’s Phase 2a-ready…
Needle-Free Vaccine Delivery Platform Aims to End Frozen Storage Needs & Improve Access
aVaxziPen’s innovative vaccine delivery platform aims to improve access to vaccines by removing the need for frozen storage and enabling easier distribution and deployment….
Anavex Life Sciences Announces Completion of Phase 2/3 Rett Syndrome Clinical Trial
Anavex Life Sciences Corp. recently announced the completion of dosing of all participants of the placebo-controlled EXCELLENCE Phase 2/3 study ANAVEX2-73-RS-003 in pediatric patients with…
Catalent Expands OneBio® Suite for Integrated Development, Manufacturing & Supply Across Biologic Modalities
Catalent recently announced it has expanded its integrated development, manufacturing and supply solution, OneBio® Suite, across a range of biologic modalities, including antibody and recombinant…
Ajinomoto Integrates R&D Sites in Japan & Korea With Genedata Bioprocess
Genedata and Ajinomoto recently announced Ajinomoto has successfully rolled out Genedata Bioprocess® to its Korean sites, Ajinomoto Genexine, in line with….
Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients With Non-Obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc. recently announced it has completed enrollment in the IMPROVE-HCM Phase 2 placebo controlled clinical trial of ninerafaxstat with 67….
Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity & Type 2 Diabetes
Enterin Inc. recently announced the start of a Phase 1a study in obesity and Type 2 diabetes (IND #155001). The study is a first-in-human, single…
NovelMed Phase 1 Clinical Trial Shows Inhibition of the Alternative Pathway & Preservation of the Classical Pathway – A Long-Acting Anti-Properdin Monoclonal Antibody for PNH Patients
NovelMed Therapeutics, Inc. recently announced topline results from First-in-Human Phase 1 clinical trial of its complement blocker monoclonal anti-Properdin antibody, known as NM3086…..
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
Synlogic, Inc. recently announced the initiation of Synpheny-3, a global, pivotal Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment…
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager in Phase 1/2 Trial for the Treatment of Advanced Melanoma & Metastatic Non-Small Cell Lung Cancer
Portage Biotech Inc. recently announced updated interim data from the Phase 1 portion of the trial evaluating its lead invariant natural killer T cell (iNKT)…
Artax Biopharma Announces Positive Phase 1 Results for Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases
Artax Biopharma, Inc. recently announced positive Phase 1 clinical trial results for AX-158, the company’s first-in-class oral small molecule immunomodulator to enter clinical development to…
Medigene Announces Pipeline Expansion Into Neoantigens With Programs Targeting Multiple KRAS Mutations & HLAs
Medigene AG recently announced its pipeline expansion into neoantigens (also known as oncogenic driver mutations) with KRAS (Kirsten rat sarcoma viral oncogene homologue) as the…
Wheeler Bio and Charles River Laboratories Announce Agreement to Build & Operate RightSource Laboratory
Wheeler Bio, Inc. and Charles River Laboratories International, Inc. recently announced an agreement to implement RightSource at Wheeler Bio’s current good manufacturing practice (cGMP) biologics manufacturing facility….
Upperton Pharma Solutions Increases Oral Dosage Form Capabilities at Its Nottingham HQ
Upperton Pharma Solutions has expanded its oral dosage form capabilities at its newly built headquarters in Nottingham, UK. Part of Upperton’s £15m investment program announced…
Coave Therapeutics Announces Positive 12-Month Data From Ongoing Phase 1/2 Clinical Trial of CTx-PDE6b in Patients With Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
Coave Therapeutics recently announces the positive 12-month results from its Phase 1/2 trial evaluating the safety and efficacy of its innovative gene therapy, CTx-PDE6b, for…
Minoryx Gains FDA Approval to Initiate Phase 3 Trial in Patients With Cerebral Adrenoleukodystrophy
Minoryx Therapeutics recently announced US FDA approval of its Phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD)…
Evonik Launches Next-Generation Peptide for Biopharma Applications
Evonik now offers cQrex® KC, a performance-boosting peptide for cell culture media used in the manufacture of biological drugs. The new peptide enables cell culture process developers….
